Michael B Streiff, MD
Disclosures: Consulting Fee-Janssen-Other_Role-Consultant for Clinical trial development|Consulting Fee-Bristol-Myers Squibb-Consultant to advise on etiology of adverse events on clinical trial|Honoraria-Pfizer, Inc.-Spoke at a webinar on cancer associated thrombosis for their global staff conference|Contracted Research-Janssen-Principal_Investigator-Cassini Trial|Consulting Fee-Bayer Corporation-Other_Role-Speaker at CME program, consultant at Advisory Board meeting|Contracted Research-Sanofi-Aventis-Principal_Investigator-Fitusiran clinical trial|Contracted Research-Coagulo Medical Technologies, Inc-Principal_Investigator-Clinical study of their POC Microfluidics device|Contracted Research-NovoNordisk-Principal_Investigator-Clinical Trial of Long-acting factor VIII concentrate for hemophilia A - 06/19/2020

Michael B. Streiff, MD, FACP

Professor of Medicine and Pathology             

Associate Faculty, Armstrong Institute for Patient Safety and Quality

Medical Director, Johns Hopkins Anticoagulation Management Service and Outpatient Clinics

Co-Medical Director, Johns Hopkins Hemostatic Disorders Stewardship Program

Medical Director, Special Coagulation Laboratory             

Medical Consultant, Johns Hopkins Comprehensive Hemophilia Treatment Center             

Johns Hopkins Medical Institutions

Baltimore, Maryland

Dr Streiff’s research focuses on the prevention and treatment of venous thromboembolism (VTE) and evidence-based management of anticoagulation. He chairs the Venous Thromboembolism Guideline Committee for the National Comprehensive Cancer Network and has served on several international consensus panels to develop evidence-based guidelines for the management of VTE. He is a member of the Anticoagulation Forum Advisory Council. He has published over 200 articles and book chapters focusing on topics in VTE management and Thrombosis and Hemostasis and delivered over 400 lectures at local, national and international meetings.